Chief Executive Officer and Board Director at Athersys, Inc
This week, Horizon Pharma announced that our Phase 3 STEADFAST trial, which involved evaluating one of our current medicines for the treatment of Frie
Pharmaceutical/Biotech executive experienced in commercial strategy, operations, analytics, market access, general management and building effective teams. Proven track record of transforming single product start-ups into high functioning multi-franchise organizations. Contributed to a successful US commercial entry of Yamanouchi Pharma in 2003 thru a merger with Fujisawa in 2005 to create Astellas Pharma, a global specialty pharmaceutical company with $3.2B in US net sales (FY2014). Joined Horizon Therapeutics in 2015 as a small specialty pharmaceutical company with ~$2B market cap and helped transform the commercial organization to become a leader in rare disease with 11 on market products and a ~$21B market cap (Jan 2022). Successfully launched 11 products (NDA’s and BLA’s) in specialty markets: Oncology, Urology, Immunology, Neurology, Dermatology, CV Imaging, Rheumatology and Orphan/Rare Disease.
Anymail finder is trusted by tens of thousands of companies to provide accurate contact information to their Sales and Business Development teams.
If you're looking to find the email of Daniel Camardo at Horizon Pharma then you've come to the right place.
Wondering if it's daniel@horizonpharma.com, daniel.camardo@horizonpharma.com, camardo@horizonpharma.com, or dcamardo@horizonpharma.com? We have the answers for you.